Attached files
| file | filename |
|---|---|
| EX-99.3 - EXHIBIT 99.3 - Shire plc | dp89900_ex9903.htm |
| EX-99.2 - EXHIBIT 99.2 - Shire plc | dp89900_ex9902.htm |
| EX-99.1 - EXHIBIT 99.1 - Shire plc | dp89900_ex9901.htm |
| 8-K - FORM 8-K - Shire plc | dp89900_8k.htm |
EXHIBIT 99.4
| Press Release |  |
| www.shire.com |
Holding(s) in Company
April 23, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Shire plc (LEI: 54930005LQRLI2UXRQ59) | |||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | ||||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify)iii: | ||||||
| 3. Details of person subject to the notification obligationiv | ||||||
| Name | Susan Kilsby (Chairman of Shire plc and proxy holder) | |||||
| City and country of registered office (if applicable) | ||||||
| 4. Full name of shareholder(s) (if different from 3.)v | ||||||
| Name | Third parties holding ADRs on behalf of the person identified in box 3 and shareholders appointing (i) the Chairman of Shire plc as proxy and (ii) a designate of Shire plc as proxy. | |||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reachedvi: | April 22, 2018 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | April 23, 2018 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | %
of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | |||
| Resulting situation on the date on which threshold was crossed or reached | 6.41% | 6.41% | 912,293,361 | |||
Position of previous notification (if applicable) |
||||||
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
| A: Voting rights attached to shares | |||||||||
Class/type
of ISIN code (if possible) |
Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
JE00B2QKY057 (Shire plc Ordinary Shares of 5 pence each) |
58,466,123 | 6.41% | |||||||
| SUBTOTAL 8. A | 58,466,123 | 6.41% | |||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
| Type of financial instrument | Expiration datex |
Exercise/
Conversion Periodxi |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights | |||||
| SUBTOTAL 8. B 1 | |||||||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
| Type of financial instrument | Expiration datex |
Exercise/
Conversion Period xi |
Physical or cash settlementxii |
Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
| ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | X | |||
| Full
chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) |
||||
| Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | Susan Kilsby (Chairman of Shire plc) | |||
| The number and % of voting rights held | 58,440,653 / 6.41% | |||
| The date until which the voting rights will be held | The conclusion of Shire plc’s Annual General Meeting to be held on April 24, 2018, or any adjournment thereof. | |||
| 11. Additional informationxvi | ||||
| The number of indirect voting rights includes 58,440,653 voting rights, being the maximum number of discretionary proxy votes held by the Chairman of Shire plc pursuant to proxies received in respect of the resolutions to be considered by shareholders at the Shire plc Annual General Meeting to be held on April 24, 2018. These voting rights will expire immediately upon the conclusion of the Annual General Meeting, or any adjournment thereof. The appointment of a proxy shall not preclude a shareholder of Shire plc from attending and voting in person at the Annual General Meeting. | ||||
| Place of completion | Dublin, Ireland |
| Date of completion | April 23, 2018 |
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | christoph.brackmann@shire.com | +41 795 432 359 |
| Sun Kim | sun.kim@shire.com | +1 617 588 8175 |
| Robert Coates | rcoates@shire.com | +44 203 549 0874 |
| Media | ||
| Katie Joyce | kjoyce@shire.com | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.
www.shire.com